Negotiations over delivery prices on a per-item unit-price basis
First written in FY2017-Q1. 15 of 19 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Gross profit was ¥49,581 million, compared with ¥49,214 million in the previous fiscal year. This was mainly attributable to the increase in sales described above and the thorough pursuit of price negotiations with transaction costs in mind.」
The thorough pursuit of price negotiations with transaction costs in mind is cited as a factor behind the increase in gross profit. - FY2024AdvancedAnnual report
「In terms of profit, in addition to the effect of higher sales, we pursued price negotiations with transaction costs in mind for each customer, recorded earnings from delivery services for COVID-19 vaccines commissioned by the national and local governments, and recorded reversal gains on a portion of the allowance for doubtful accounts for a major customer recognized in the previous fiscal year. As a result, the results substantially exceeded the previous year's results.」
States that price negotiations with transaction costs in mind for each customer, together with vaccine-delivery earnings and other factors, contributed to pharmaceutical wholesale business profit substantially exceeding the previous year's results. - FY2024-Q3AdvancedAnnual report
「In terms of profit, in addition to the effect of higher sales, the results substantially exceeded the previous year's results as a result of pursuing price negotiations with transaction costs in mind for each customer.」
States that price negotiations with transaction costs in mind for each customer led to results in terms of profit that substantially exceeded the previous year's results. - FY2024-Q2RestatedAnnual report
「In terms of profit, in addition to the effect of higher sales, we recorded earnings from pursuing price negotiations with transaction costs in mind for each customer, as well as」
Continues efforts to pursue price negotiations with transaction costs in mind for each customer and record earnings. - FY2023-Q2RestatedAnnual report
「In terms of profit, we thoroughly conducted price negotiations with transaction costs in mind, and」
Continues price negotiations with transaction costs in mind as a measure to secure profit and conduct transactions at appropriate prices. - FY2022RestatedAnnual report
「During the consolidated fiscal year under review, in order to maintain a stable supply system, we made every effort, in line with the purpose of the Distribution Improvement Guidelines, to promote negotiations over per-item pricing and conduct transactions at appropriate prices that reflect the value of pharmaceuticals.」
Continues negotiations over per-item pricing and transactions at appropriate prices that reflect the value of pharmaceuticals as measures to maintain a stable supply. - FY2022-Q3RestatedAnnual report
「During the third quarter of the consolidated cumulative period under review, in order to maintain a stable supply system, we have made every effort, in line with the purpose of the Distribution Improvement Guidelines, to promote negotiations over per-item pricing and conduct transactions at appropriate prices that reflect the value of pharmaceuticals.」
Continues to promote negotiations over per-item pricing and conduct transactions at appropriate prices that reflect the value of pharmaceuticals. - FY2022-Q2RestatedAnnual report
「During the consolidated cumulative period under review, in order to maintain a stable supply system, we have made every effort, in line with the purpose of the Distribution Improvement Guidelines, to promote negotiations over per-item pricing and conduct transactions at appropriate prices that reflect the value of pharmaceuticals.」
Negotiations over per-item pricing, which could not be sufficiently promoted in the previous fiscal year, continue together with transactions at appropriate prices in line with the Distribution Improvement Guidelines. - FY2022-Q1RestatedAnnual report
「In line with the purpose of the Distribution Improvement Guidelines, we are making every effort to promote negotiations over per-item pricing and conduct transactions at appropriate prices that reflect the value of pharmaceuticals.」
Negotiations over per-item pricing, which could not be sufficiently promoted in the previous fiscal year, are being pursued again together with transactions at appropriate prices in line with the Distribution Improvement Guidelines. - FY2019RestatedAnnual report
「We have also focused on promoting negotiations over per-item pricing, one of the distribution-improvement initiatives being pursued across the pharmaceutical wholesale industry.」
Continues to promote negotiations over per-item pricing as a distribution-improvement measure. - FY2019-Q3RestatedAnnual report
「We have also focused on promoting negotiations over per-item pricing, one of the distribution-improvement initiatives being pursued across the pharmaceutical wholesale industry.」
Continues to promote negotiations over per-item pricing as a distribution-improvement measure. - FY2019-Q2RestatedAnnual report
「We have also focused on promoting negotiations over per-item pricing, one of the distribution-improvement initiatives being pursued across the pharmaceutical wholesale industry.」
Continues to promote negotiations over per-item pricing as a measure to address category changes and improve distribution. - FY2018RestatedAnnual report
「Our group has focused on promoting negotiations over per-item pricing, one of the distribution-improvement initiatives being pursued across the pharmaceutical wholesale industry.」
Continues to promote negotiations over per-item pricing as a distribution-improvement measure. - FY2018-Q3RestatedAnnual report
「We have also focused on promoting negotiations over per-item pricing, one of the distribution-improvement initiatives being pursued across the pharmaceutical wholesale industry.」
Continues to promote negotiations over per-item pricing as a distribution-improvement measure. - FY2018-Q2RestatedAnnual report
「We have also focused on promoting negotiations over per-item pricing, one of the distribution-improvement initiatives being pursued across the pharmaceutical wholesale industry.」
Negotiations over per-item pricing are continuing as a measure to address category changes and other issues. - FY2018-Q1RestatedAnnual report
「We have also focused on promoting negotiations over per-item pricing, one of the distribution-improvement initiatives being pursued across the pharmaceutical wholesale industry.」
Negotiations over per-item pricing are continuing as a measure to address category changes and other issues. - FY2017RestatedAnnual report
「We have also focused on negotiations over delivery prices based on per-item pricing as an appropriate response to category changes.」
Negotiations over delivery prices based on per-item pricing are continuing as a measure to address category changes. - FY2017-Q2RestatedAnnual report
「In terms of profit, we have worked to generate profit through joint procurement with some manufacturers, while also focusing on negotiations over delivery prices based on per-item pricing as an appropriate response to category changes.」
Negotiations over delivery prices based on per-item pricing are continuing as a measure to address category changes. - FY2017-Q1First statedAnnual report
「In terms of profit, we have worked to generate profit through joint procurement with some manufacturers, while also focusing on negotiations over delivery prices based on per-item pricing as an appropriate response to category changes.」
Negotiations over delivery prices based on per-item pricing are being pursued as a measure to address category changes.